Developing reliable & safe metered dose inhalers (devices) for Healthcare Cannabis markets in the America’s
Cannabis is rapidly becoming an accepted form of medical intervention. While its global regulations remain highly complicated, many countries are enabling its use for medical purposes. In North America, laws covering recreational and medical use of cannabis are present in Canada and in several States in the USA. Europe is rapidly adopting regulations that will also enable many people to determine if medical cannabis is right for them. Globally, it is estimated that the legal cannabis market will reach $47Billion (USD) by 2025.
Despite these rapid regulatory and legal advances, the cannabis sector is marked with many challenges in particular in product purity, dosing and quality and safety. In the last two years, the United States has experienced a ‘vaping crisis’ with 60 deaths and over 2000 hospital admissions being linked to the vaping of cannabis oil products. Delivering the active ingredients of cannabis (primarily the oils of THC and CBD) in a safe, reliable and effective manner has become a key challenge for the industry.
During the webinar, H&T Presspart and Concept Global 1, will introduce participants to metered-dose devices (MDDs) as an effective and safe form of oral lung delivery. The webinar will discuss how regulations across North America and Europe vary and how these devices can be optimized in order to deliver accurate dosing. The webinar will also discuss key features and benefits of MDD’s for the cannabis market and how to select the optimal components for an MDD device, including testing requirements to ensure effective delivery to meet the needs of the patient or user.
Participants will also get an understanding of how to develop a cannabis formulation for metered-dose devices and how to industrialise the product including filling and packaging requirements.
This webinar is designed for anyone who wants a better understanding of metered-dose devices and the benefits if offers a patient/user for effective delivery of highly purified cannabis oil. This webinar is also of interest to those wishing to understand how to rapidly bring these devices to their local market.
Business Development and Sales Manager
Graduating from the University of Nebraska at Omaha, Jay Polanco has worked for over 15 years in the Pharmaceutical and biotech industry in the USA and Europe, where he has held different positions in commercial, market research, business development, and licensing. Jay has been with H&T Presspart for over 11 years, where he has been responsible initially for Sales and Business Development in the European and North African market. For five years Jay was in charge of Sales and Business Development in the Latin America market. Currently, Jay is in charge of Sales and Business Development for North America. Jay can speak numerous languages fluently, including English, Spanish, Catalan, French, Portuguese and Italian.
Global Business Development Manager
With a strong pharmaceutical and analytical background, Jacqueline is currently based at H&T Presspart’s Blackburn, UK site, working within the Business Development team to provide technical expertise and support on every aspect of MDIs. Jacqueline is also responsible for the management of all Cannabis related projects across the globe. Jacqueline previously worked within H&T Presspart’s Inhalation Product Technology Centre, undertaking a wide range of invitro analytical testing for MDI’s and formulations to support our customers product development.
Michael Mayne, PhD,
Co-Managing Partner Concept Global One LLC
Dr Mayne is trained as a cell biologist and pharmacologist and started his career teaching pharmacology and therapeutics at the University of Manitoba in Canada. Dr Mayne subsequently served for 15 years as a senior executive in federal and provincial governments in Canada. He served on numerous national Boards including the Canadian Agency for Drugs and Technologies in Health, Canada Health Infoway, and the National Commission on Mental Health and Addictions. He also served as a Deputy Minister of Industry and CEO of a regional Health Authority in Canada. He has extensive experience in drug regulations and guidelines and as Co-Chair lead of the Premiers Health Care Working Group (2011-2014), he helped to modernize the way in which Canada reimburses for prescription generic and brand medication.
Dr Mayne left the public sector in 2017 to start his own consulting and strategy agency. He provides regulatory and strategic advice to clients in the pharmaceutical, healthcare, IT and medical device sectors. Dr Mayne became a founding partner in Concept Global One LLC, a company that focuses on bringing safe and high quality aerosol devices to the global cannabis markets.